Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Cardiff Oncology (CRDF) Accumulated Depreciation & Amortization (2016 - 2025)

Cardiff Oncology's Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 7.98% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, up 7.98%, while the annual FY2025 figure was $4.5 million, 7.98% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $4.5 million at Cardiff Oncology, up from $4.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $4.5 million in Q4 2025 and bottomed at $31000.0 in Q1 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $236000.0 (2022), against an average of $1.3 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization plummeted 73.95% in 2022 before it soared 4047.06% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $451000.0 in 2021, then tumbled by 47.67% to $236000.0 in 2022, then surged by 68.64% to $398000.0 in 2023, then skyrocketed by 939.45% to $4.1 million in 2024, then grew by 7.98% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Accumulated Depreciation & Amortization are $4.5 million (Q4 2025), $4.4 million (Q2 2025), and $4.2 million (Q1 2025).